PhenoNet Cleared by FDA to Begin Phase 3 Trial of Inhaled PHENOGENE-1A in Early Alzheimer's Disease
U.S. Food and Drug Administration (FDA) has notified the company that it may proceed with a Phase 3 clinical trial of its lead candidate, PHENOGENE-1A...